Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEM/RZR DDI with Buprenorphine/Naloxone or Methadone
NCT07314346Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Jan 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bemnifosbuvir and ruzasvir in hepatitis C (HCV) (2 arms), sponsored by Atea Pharmaceuticals. Primary endpoints: Pharmacokinetics of buprenorphine, norbuprenorphine, and naloxone and Pharmacokinetics of methadone. Started Jan 2025; status: completed.
02
Drugs
bemnifosbuvirruzasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT07314346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07314346.